RxDoctor Payments Data

Stephen Ross, MD

Family Medicine · Oklahoma City, OKNPI 1679131387

Payments from drug & device makers

$195in general payments, 2019–2025

Across 11 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$78
  • AstraZeneca$50
  • Exact Sciences$24
  • Lilly USA, LLC$17
  • Dexcom, Inc.$14
  • AbbVie$13

What the payments were for

  • Food & beverage$195100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK4$78
AstraZeneca3$50
Exact Sciences1$24
Lilly USA, LLC1$17
Dexcom, Inc.1$14
AbbVie1$13

How this compares

$195 in reported general payments places this provider in the 35th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$101,077
Medicare patients
253
Services billed
2,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$78,742
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$76,599
OzempicSemaglutide23$43,325
MounjaroTirzepatide18$28,482
FarxigaDapagliflozin Propanediol24$28,459
JardianceEmpagliflozin25$23,457
LinzessLinaclotide24$22,222
XareltoRivaroxaban14$11,648
MyrbetriqMirabegron19$9,461
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,253
Gabapentin222$5,728
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen119$5,538
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen138$4,598
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$4,310
Tresiba Flextouch U-100Insulin Degludec14$4,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$78$76,59981 claims
AstraZenecaFarxiga, Breztri Aerosphere$50$36,71235 claims
Lilly USA, LLCMounjaro$17$28,48218 claims
AbbVieLinzess$13$22,22224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →